Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Roku, Inc. (ROKU) - free report >>
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roku, Inc. (ROKU) - free report >>
Image: Bigstock
Best Momentum Stocks to Buy for July 17th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 17th:
ProKidney Corp. (PROK - Free Report) : This clinical-stage biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.8% over the last 60 days.
ProKidney Corp. Price and Consensus
ProKidney Corp. price-consensus-chart | ProKidney Corp. Quote
ProKidney’s shares gained 371.7% over the last three months compared with the S&P 500’s advance of 18.2%. The company possesses a Momentum Score of A.
ProKidney Corp. Price
ProKidney Corp. price | ProKidney Corp. Quote
Roku, Inc. (ROKU - Free Report) : This operator of a TV streaming platform has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.3% over the last 60 days.
Roku, Inc. Price and Consensus
Roku, Inc. price-consensus-chart | Roku, Inc. Quote
Roku’s shares gained 55.4% over the last three months compared with the S&P 500’s advance of 18.2%. The company possesses a Momentum Score of B.
Roku, Inc. Price
Roku, Inc. price | Roku, Inc. Quote
Pharming Group N.V. (PHAR - Free Report) : This biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing nearly 7% over the last 60 days.
Pharming Group N.V. Sponsored ADR Price and Consensus
Pharming Group N.V. Sponsored ADR price-consensus-chart | Pharming Group N.V. Sponsored ADR Quote
Pharming’s shares gained 26.6% over the last three months compared with the S&P 500’s advance of 18.2%. The company possesses a Momentum Score of B.
Pharming Group N.V. Sponsored ADR Price
Pharming Group N.V. Sponsored ADR price | Pharming Group N.V. Sponsored ADR Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.